Nuvation Bio's Stock Price More Than Doubles Year-on-Year
Nuvation Bio (NUVB) stock has more than doubled in value over the past year, rising 156.7%, with a 40.79% increase year-to-date. The company amended its license agreement with Daiichi Sankyo to include Japan rights for safusidenib, a drug in Phase 3 trials for IDH1-mutant glioma.
Tickers: $NUVB
Topics: biotech drug development IDH1-mutant glioma license agreement stock performance